Insulet announced at the Consumer Electronics Show that it will showcase its Omnipod 5 system, the first automated insulin delivery device approved for both type 1 and type 2 diabetes, and will demonstrate its integration with continuous glucose monitoring and smartphone controls.
The announcement follows Q3 2025 results in which revenue rose 28.2% to $706.3 million, driven by robust demand for Omnipod 5 in the United States ($497.1 million) and internationally ($202.1 million). Gross margin expanded to 72.2% from 72.1% in Q4 2024, reflecting pricing power and disciplined cost management.
CEO Ashley McEvoy said the results underscore the transformative power of Omnipod 5 and that the company is on track to deliver a 28‑29% revenue growth for the full year, a guidance increase that signals confidence in continued demand.
Insulet also highlighted its strategy to broaden the Omnipod ecosystem, including the launch of a new data‑insights platform called Discover in 2026 and ongoing development of Omnipod 6 and a closed‑loop system for type 2 diabetes expected in 2028.
Investors reacted positively to the announcement, citing the strong revenue growth, margin expansion, and guidance as evidence of robust execution and a growing market share in the automated insulin delivery space.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.